AlphAIAlphAI — Financial news for AI agents
theglobeandmail.comSEP 161 min read$KMB

Kimberly Clark (KMB) Receives a Buy from RBC Capital

RBC Capital's Nik Modi maintained a Buy rating on Kimberly Clark (KMB) with a $162 price target. The stock closed at $98.15. Analysts have a Moderate Buy consensus with a $115.83 average target. Q2 revenue was $4.19B, down from $4.16B YoY, with net profit decreasing from $509M to $345M.

Original reporting
theglobeandmail.com
Published Sep 16, 2026, 1:58 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 6:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Kimberly Clark (KMB) Receives a Buy from RBC Capital — source image
Source · theglobeandmail.com
Decision brief

The 30-second read

$KMBBullishLow
01

Why it matters

Analyst coverage may influence short‑term sentiment but lacks fresh material.

02

Market read

Limited relevance; primarily an analyst opinion piece.

03

What to watch

No new earnings or guidance data accompanies the rating.

Relevance 4/10Novelty 2/10Timing: post‑report, no immediate catalyst

Background

The article recaps recent analyst coverage for Kimberly Clark, including price targets from RBC Capital and Piper Sandler.

Company-level read

Ticker impact

$KMBBullishLow confidence
Context

RBC Capital maintained a Buy rating and set a $162 price target for Kimberly Clark.

Expected impact

Potential slight price appreciation if investors follow the new target.

Evidence & confidence

Rating unchanged; price target increase is modest and not time-sensitive.

Market effects

Sector

Minor impact on Consumer Defensive sector as peers receive similar coverage.

Regional

Limited to U.S. market where KMB trades.

Global

Low global relevance.

Counterpoint

What could challenge this read

Investors may view the unchanged rating as a sign of limited upside.

Key entities

  • Company
    Kimberly Clark

    Consumer goods manufacturer (ticker KMB).

  • Analyst
    RBC Capital

    Maintained Buy rating and raised price target.

Read at source← All news

Related articles

SEP 15
$KMBHighAI 9/10

Kimberly-Clark Moves to Clear EU Hurdle with Kenvue Asset Sales

Kimberly-Clark (KMB) is selling assets to address EU antitrust concerns over its $40B Kenvue acquisition, aiming for approval by September 29. The deal, expected to create a $32B revenue company, faces similar scrutiny in Australia. KMB anticipates $1.9B in annual cost synergies but may need to divest assets to secure approval.

yahoo.com2 min
SEP 14
$KMBMedAI 8/10

KMB Looks 18.8% Undervalued on GF Value™ Amid Dividend Concerns

Kimberly-Clark (KMB) shares rose 2.5% after announcing adjustments to address EU antitrust concerns over its $40B Kenvue (KVUE) acquisition. The EU decision deadline is September 29. KMB offers a 5.09% dividend yield but has a high payout ratio of 0.89, raising sustainability concerns. Its GF Value™ suggests the stock is 18.8% undervalued, with a GF Score™ of 72/100.

gurufocus.com2 min
SEP 14
$KVUEMedAI 8/10

Here's My Pick for the Smartest High-Yield Dividend Stock to Buy Right Now

Kenvue (KVUE) is highlighted as a strong high-yield dividend stock with a 4.68% yield and 64 years of consecutive dividend increases. Its stable of well-known brands reported Q2 revenue of $3.95B and EPS of $0.24. The company is being acquired by Kimberly-Clark (KMB), another Dividend King, which may create uncertainty about Kenvue's dividend.

fool.com2 min
SEP 14
$KMBHighAI 9/10

Exclusive-Kimberly-Clark prepares asset sales to win EU nod for Kenvue deal, sources say

Kimberly-Clark is preparing asset sales to address EU antitrust concerns regarding its $40 billion acquisition of Kenvue. The European Commission is expected to formally raise its concerns this week. Kimberly-Clark shares rose 2.7% and Kenvue gained 2.3% on the news. The deal, announced in November, would expand Kimberly-Clark's product range to include Kenvue's brands like Listerine, Aveeno, and Neutrogena.

live.euronext.com2 min
SEP 14
$KMBHighAI 9/10

Health Giants Make Big Moves and Discoveries

Kimberly-Clark negotiates EU regulators for $40B Kenvue acquisition, offering concessions. Definium Therapeutics' LSD-based drug reduced anxiety in trials. Scholar Rock's SMA drug priced at $11,659 per vial. Electra Therapeutics targets $977.6M IPO valuation. BioNTech's lung cancer treatment shows trial success.

devdiscourse.com3 min